Please login to the form below

Not currently logged in
Email:
Password:

Merck Serono/Affectis agree P2X7 deal

Affectis Pharmaceutical and Merck Serono have signed a deal for the development and commercialisation of oral compounds targeting P2X7 receptors

Affectis Pharmaceutical, based in Munich, Germany, has signed a licensing agreement with Merck Serono for the development and commercialisation of oral compounds targeting P2X7 receptors.

P2X7 is an ATP-gated ion channel receptor that is essential for the maturation and release of the pro-inflammatory cytokines. P2X7 is found on brain cells, which are activated by high levels of ATP in conditions of neuroinflammation.

Under the terms of the agreement, Merck Serono will have worldwide exclusive rights to develop and commercialise selected compounds. The contract also includes a research collaboration focusing on P2X7 antagonist optimisation. Affectis will receive €2.4m in upfront payment and research funding, and could receive up to €277m in milestones for the first three products to come out of the collaboration, as well as undisclosed royalties.

Dr Michael Boes, chief scientist officer of Affectis, said: "Affectis' chemistry expertise puts special emphasis on brain penetration, which supports our development of oral P2X7 antagonists for the potential treatment of central nervous system diseases."

8th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics